Israel’s Averna Therapeutics (formerly Exsilio Therapeutics) is using gene editing to develop medicines to cure rare genetic diseases. Averna’s leadership includes Tal Zaks who was Chief Medical Officer at Covid-19 vaccine developer Moderna. Averna has already raised $82 million in funds.
https://en.globes.co.il/en/article-tal-zaks-israeli-startup-targets-rare-genetic-diseases-1001500636